Seoul Economic Daily EnglishDoubao · 实盘不做把握 4/10不做原因:无增量信息
北京时间·🕒 发布 10:02:50(首尔 11:02)·⟳ 抓取 10:12:35 +9m45s·⚡ 决策 09-14 10:15:21 +2m46s·43.8 天前
爱茉莉太平洋投资者日提出2035年集团营收15万亿韩元等长期增长目标
这是投资者日上的长期战略蓝图：15万亿韩元目标对应2035年，皮肤科美容和护发1万亿韩元目标对应FY2030，最近的FY2027目标也只是10%收入增长和11%以上营业利润率。公告未给出新增订单、并购、回购、当期业绩上修或超预期量化信息，且投资者日实际发生在9月11日、9月14日才由英文媒体报道，短线交易价值有限。
📄 原文Seoul Economic Daily English↗ 原文
Amorepacific Targets 15 Trillion Won in Sales by 2035
Amorepacific (090430.KS) will build up its dermatology-focused beauty and hair care businesses as global growth drivers…
不做 Amorepacific（090430.KS）
长期投资者日战略目标缺少近端、可量化的超预期财务增量；关键目标兑现期在FY2027至2035年，且投资者日早在9月11日举行，短线风险收益不明确。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
爱茉莉太平洋公布长期全球增长目标，但核心数字均为多年战略愿景而非近端业绩兑现，难以形成可交易的预期差；唯一直接标的090430.KS不做。
🔎 新鲜度:最早出现 2026-09-11 · 扩散 low · price-in 风险 medium ↗
关键理由
- 品牌扩张和利润率目标方向正面，但兑现期跨越FY2027至2035，不能直接转化为未来1至5个交易日的盈利增量。
- 投资者日于9月11日举行，英文报道时间为9月14日，材料可能已在韩国本地市场提前消化。
主要风险
- 若卖方将FY2027 10%增长和11%营业利润率解读为显著高于一致预期，股价可能继续获得估值重估。
- 无法取得090430.KS实时报价，不能确认韩国盘中是否已出现大幅高开或放量反应。
反向证据
- 做多前查反向 · 来源 web · 影响 weakens
本轮未发现可核验的新增订单、当期业绩上修或显著超预期证据；事件本身是长期目标披露。
检索:Amorepacific Investor Day 2026 guidance already expected analyst reaction September 2026 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例不足叠加事件本身缺乏近端财务增量，最终选择不交易而非凭长期愿景追高。
方向:未形成足够的同市场、同相位、首发可核验先例面板；长期投资者日目标通常更偏估值叙事，不能据此校准短线涨幅。
涨幅量级:缺少韩国消费股投资者日长期目标发布后的高相似对齐样本，不能设定可靠止盈区间。
形态:未确认反复见光死模式，也未确认持续上涨模式。
工具执行结果 · 成功 1 · 降级 1 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 14 ms
{"result": "search_processed_events:agent query=`0904430 amorepacific fiscal 2027 operating margin 11% guidance | amorepacific aestura illiyoon dermatology beauty hair care global strategy | amorepacific investor day 2026 15 tril`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 0.0/72 小时、0 条本臂决策(完整)，返回 0 条候选。未命中只表示这些 agen - stock_quote 降级 stock_tools HTTP · 10,061 ms
取价失败: TimeoutError:
原文全文
展开原文 · 2,227 字
Amorepacific (090430.KS) will build up its dermatology-focused beauty and hair care businesses as global growth drivers as it targets 15 trillion won ($10.8 billion) in group revenue by 2035.
The company said on Sept. 14 that it unveiled global growth strategies for its dermatology beauty and hair care brands at its 2026 Investor Day, held on Sept. 11 at its headquarters in Yongsan, Seoul. In dermatology beauty, the company will expand overseas around its Aestura and Illiyoon brands, aiming for 1 trillion won in revenue from dermatology beauty brands in fiscal 2030, which runs from July 2029 to June 2030.
Aestura, which has entered 36 countries over the past three years, will add nine more markets by the first half of next year to accelerate its global expansion. Illiyoon will develop its Ato Cream as a flagship global product, while IOPE will enter the European market in the first half of next year following its launch at Sephora in the U.S., with a goal of becoming a brand generating 500 billion won in revenue by 2035.
The company is also stepping up its hair care push. Building on a multi-brand portfolio that includes Ryo and Mise en Scene, it aims for 1 trillion won in revenue by fiscal 2030. To lift the share of overseas sales above 60%, it will expand in major markets including the U.S., China, Japan and Brazil, focusing on premium hair care and scalp care while developing flagship global products for each brand.
Amorepacific will also strengthen its digital capabilities. It plans to broaden consumer touchpoints on major digital channels such as social media and e-commerce, and to refine its marketing using consumer data and insights by market and channel. Through these efforts, the company aims for 10% revenue growth and an operating margin of more than 11% in fiscal 2027, the year running from July 2026 to June 2027.
"We will accelerate the growth of our existing flagship brands and develop dermatology beauty, clinical skin care and hair care into new global growth pillars," Amorepacific CEO Kim Seung-hwan said. "We will respond nimbly to changes in customers and markets driven by social media, e-commerce and artificial intelligence to create sustainable growth in global markets."
The company said on Sept. 14 that it unveiled global growth strategies for its dermatology beauty and hair care brands at its 2026 Investor Day, held on Sept. 11 at its headquarters in Yongsan, Seoul. In dermatology beauty, the company will expand overseas around its Aestura and Illiyoon brands, aiming for 1 trillion won in revenue from dermatology beauty brands in fiscal 2030, which runs from July 2029 to June 2030.
Aestura, which has entered 36 countries over the past three years, will add nine more markets by the first half of next year to accelerate its global expansion. Illiyoon will develop its Ato Cream as a flagship global product, while IOPE will enter the European market in the first half of next year following its launch at Sephora in the U.S., with a goal of becoming a brand generating 500 billion won in revenue by 2035.
The company is also stepping up its hair care push. Building on a multi-brand portfolio that includes Ryo and Mise en Scene, it aims for 1 trillion won in revenue by fiscal 2030. To lift the share of overseas sales above 60%, it will expand in major markets including the U.S., China, Japan and Brazil, focusing on premium hair care and scalp care while developing flagship global products for each brand.
Amorepacific will also strengthen its digital capabilities. It plans to broaden consumer touchpoints on major digital channels such as social media and e-commerce, and to refine its marketing using consumer data and insights by market and channel. Through these efforts, the company aims for 10% revenue growth and an operating margin of more than 11% in fiscal 2027, the year running from July 2026 to June 2027.
"We will accelerate the growth of our existing flagship brands and develop dermatology beauty, clinical skin care and hair care into new global growth pillars," Amorepacific CEO Kim Seung-hwan said. "We will respond nimbly to changes in customers and markets driven by social media, e-commerce and artificial intelligence to create sustainable growth in global markets."
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。